Clinical Trial Update: Single Agent Alimta in Poor Performance Status in Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Alimta (pemetrexed) as a single-agent therapy in patients with non-small cell lung cancer and poor performance status has completed, wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-02-13